Eli Lilly Stock Surges: Drug Pricing Deal Boost

Eli Lilly's stock surged 5% on drug pricing deal news, but is it a game-changer? Find out how this potential agreement, aimed at lowering US prescription costs, is impacting the pharma giant amidst recent trial setbacks and market volatility. We break down the short-term pop versus long-term investor confidence and Eli Lilly's overall performance. Hosted on Acast. See acast.com/privacy for more information.